Sign In
Buy ADPT
$22.57
-1.61 (-6.66%)
At Close: Jul 31, 2026
Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
08:00pm, Thursday, 01'st Aug 2024
Although the revenue and EPS for Adaptive Biotechnologies (ADPT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare w
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
07:20pm, Thursday, 01'st Aug 2024
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.33 per share a year ago.
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
04:05pm, Thursday, 01'st Aug 2024
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gen
3 Precision Medicine Stocks Tailoring Treatments
06:00am, Sunday, 21'st Jul 2024
Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
04:05pm, Thursday, 11'th Jul 2024
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers More than 20 abstracts will be presented
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
04:05pm, Wednesday, 29'th May 2024
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syste
Mighty Mites: 3 Small-Cap Stocks Packing a Powerful Punch
06:00am, Thursday, 23'rd May 2024
To be completely upfront, small-cap stocks to buy are risky. They're the equivalent of plus-money bets or plus odds.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:15am, Wednesday, 22'nd May 2024
Cathie Wood bought shares of Shopify, Intellia, and Adaptive Biotechnologies on Tuesday. Shopify has surrendered 26% of its value over the past two weeks since posting disappointing guidance.
Why Adaptive Biotechnologies Topped the Market Today
06:43pm, Wednesday, 08'th May 2024
On a relatively sleepy day for the market, the biotech enjoyed a decent little price pop on earnings. Its first quarter results topped analyst estimates on both the top and bottom lines.
Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript
08:59pm, Tuesday, 07'th May 2024
Adaptive Biotechnologies Corporation. (NASDAQ:ADPT ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Kyle Pis
Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics
08:30pm, Tuesday, 07'th May 2024
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wal
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Misses Revenue Estimates
06:41pm, Tuesday, 07'th May 2024
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.40 per share a year ago.
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
04:05pm, Tuesday, 07'th May 2024
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
04:05pm, Wednesday, 17'th Apr 2024
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys
